Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278717 | 0.91 | FFAR1 (0.32) | FFAR1CPT2TDP1 | |
| SCHEMBL10257462 | 0.86 | — | — | |
| SCHEMBL3280736 | 0.86 | CYP4F2 (0.37) | FFAR1CPT2TDP1 | |
| SCHEMBL3280838 | 0.83 | FFAR1 (0.38) | FFAR1CPT2TDP1 | |
| SCHEMBL3279459 | 0.82 | FFAR1 (0.31) | FFAR1CPT2TDP1 | |
| SCHEMBL3279853 | 0.81 | FFAR1 (0.41) | FFAR1CPT2TDP1 | |
| SCHEMBL3279852 | 0.81 | FFAR1 (0.37) | FFAR1CPT2TDP1 | |
| SCHEMBL31565174 | 0.80 | NAALAD2 (0.43) | FFAR1CPT2TDP1 | |
| SCHEMBL3279646 | 0.80 | NAALAD2 (0.43) | FFAR1CPT2TDP1 | |
| SCHEMBL3279908 | 0.79 | FFAR1 (0.45) | FFAR1CPT2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304093-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | claimed |
| EP-1564200-A1 | Ketone compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1326822-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-20030078239-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-04-24 | — | — | US | claimed |
| WO-2002030860-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2003-02-20 | — | — | WO | claimed |
| WO-2002030860-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| US-8975300-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975300-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140228439-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228439-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8642653-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642653-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
| EP-1701931-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1564200-A1 | Ketone compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005068412-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-6699910-B2 | TREATING AND PREVENTING CARDIOVASCULAR DISEASES, DYSLIPIDEMIAS, AND GLUCOSE METABOLISM AS HYPOGLYCEMIC AGENTS, USE TO REDUCE THE FAT CONTENT OF MEAT IN LIVESTOCK AND REDUCE THE CHOLESTEROL CONTENT OF EGGS | ESPERION THERAPEUTICS, INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1326822-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030860-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, CETP | FFAR1 137/4885CPT2 88/4885TDP1 2037/4885 |
| US-20140228439-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | FFAR1 126/4885CPT2 102/4885TDP1 1892/4885 |
| US-20030078239-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | FFAR1 126/4885CPT2 102/4885TDP1 1892/4885 |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | FFAR1 126/4885CPT2 102/4885TDP1 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.